PMV Pharmaceuticals, Inc. Email Format
Biotechnology ResearchNew Jersey, United States51-200 Employees
PMV Pharmaceuticals is a mid-sized biotechnology company focused on precision oncology, pursuing therapies that selectively target mutant p53 to disrupt cancer progression. Based in Princeton, New Jersey, the company aims to deliver treatments for patients whose tumors carry p53 mutations, addressing a broad spectrum of cancers driven by this alteration. Working in the biotechnology research sector, PMV's efforts center on advancing targeted therapies for p53-mutant cancers. Recent activity includes collaborations with MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center to support an investigator-initiated Phase 1b study of rezatapopt, both as a monotherapy and in combination with azacitidine, for patients with recurrent or refractory AML/MDS bearing a TP53 Y220C mutation. Earlier in 2024, the company announced prioritization of PC14586 clinical development.